278 related articles for article (PubMed ID: 30400243)
1. Stable Isotope-Labeled Lipidomics to Unravel the Heterogeneous Development Lipotoxicity.
Shih LM; Tang HY; Lynn KS; Huang CY; Ho HY; Cheng ML
Molecules; 2018 Nov; 23(11):. PubMed ID: 30400243
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis.
Yang RX; Pan Q; Liu XL; Zhou D; Xin FZ; Zhao ZH; Zhang RN; Zeng J; Qiao L; Hu CX; Xu GW; Fan JG
Lipids Health Dis; 2019 Oct; 18(1):179. PubMed ID: 31639005
[TBL] [Abstract][Full Text] [Related]
3. Myristic acid potentiates palmitic acid-induced lipotoxicity and steatohepatitis associated with lipodystrophy by sustaning de novo ceramide synthesis.
Martínez L; Torres S; Baulies A; Alarcón-Vila C; Elena M; Fabriàs G; Casas J; Caballeria J; Fernandez-Checa JC; García-Ruiz C
Oncotarget; 2015 Dec; 6(39):41479-96. PubMed ID: 26539645
[TBL] [Abstract][Full Text] [Related]
4. Magnesium Isoglycyrrhizinate Reduces Hepatic Lipotoxicity through Regulating Metabolic Abnormalities.
Lu L; Hao K; Hong Y; Liu J; Zhu J; Jiang W; Zhu Z; Wang G; Peng Y
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070938
[TBL] [Abstract][Full Text] [Related]
5. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease.
Svegliati-Baroni G; Pierantonelli I; Torquato P; Marinelli R; Ferreri C; Chatgilialoglu C; Bartolini D; Galli F
Free Radic Biol Med; 2019 Nov; 144():293-309. PubMed ID: 31152791
[TBL] [Abstract][Full Text] [Related]
6. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
7. Ginkgolide A ameliorates non-alcoholic fatty liver diseases on high fat diet mice.
Jeong HS; Kim KH; Lee IS; Park JY; Kim Y; Kim KS; Jang HJ
Biomed Pharmacother; 2017 Apr; 88():625-634. PubMed ID: 28142119
[TBL] [Abstract][Full Text] [Related]
8. How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?
Geng Y; Faber KN; de Meijer VE; Blokzijl H; Moshage H
Hepatol Int; 2021 Feb; 15(1):21-35. PubMed ID: 33548031
[TBL] [Abstract][Full Text] [Related]
9. Natural Product Skatole Ameliorates Lipotoxicity-Induced Multiple Hepatic Damage under Hyperlipidemic Conditions in Hepatocytes.
Hong SH; Hong Y; Lee M; Keum BR; Kim GH
Nutrients; 2023 Mar; 15(6):. PubMed ID: 36986221
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of hepatic fatty acid compositions in patients with nonalcoholic steatohepatitis.
Yamada K; Mizukoshi E; Sunagozaka H; Arai K; Yamashita T; Takeshita Y; Misu H; Takamura T; Kitamura S; Zen Y; Nakanuma Y; Honda M; Kaneko S
Liver Int; 2015 Feb; 35(2):582-90. PubMed ID: 25219574
[TBL] [Abstract][Full Text] [Related]
11. Attenuated lipotoxicity and apoptosis is linked to exogenous and endogenous augmenter of liver regeneration by different pathways.
Weiss TS; Lupke M; Ibrahim S; Buechler C; Lorenz J; Ruemmele P; Hofmann U; Melter M; Dayoub R
PLoS One; 2017; 12(9):e0184282. PubMed ID: 28877220
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease.
Kurek K; Piotrowska DM; Wiesiołek-Kurek P; Łukaszuk B; Chabowski A; Górski J; Zendzian-Piotrowska M
Liver Int; 2014 Aug; 34(7):1074-83. PubMed ID: 24106929
[TBL] [Abstract][Full Text] [Related]
13. Lactoferrin attenuates fatty acid-induced lipotoxicity via Akt signaling in hepatocarcinoma cells.
Morishita S; Tomita K; Ono T; Murakoshi M; Saito K; Sugiyama K; Nishino H; Kato H
Biochem Cell Biol; 2015 Dec; 93(6):566-73. PubMed ID: 26335364
[TBL] [Abstract][Full Text] [Related]
14. Oleic acid protects saturated fatty acid mediated lipotoxicity in hepatocytes and rat of non-alcoholic steatohepatitis.
Chen X; Li L; Liu X; Luo R; Liao G; Li L; Liu J; Cheng J; Lu Y; Chen Y
Life Sci; 2018 Jun; 203():291-304. PubMed ID: 29709653
[TBL] [Abstract][Full Text] [Related]
15. Non-alcoholic fatty liver disease: Insights from sphingolipidomics.
Montefusco DJ; Allegood JC; Spiegel S; Cowart LA
Biochem Biophys Res Commun; 2018 Oct; 504(3):608-616. PubMed ID: 29778532
[TBL] [Abstract][Full Text] [Related]
16. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
Bellanti F; Villani R; Facciorusso A; Vendemiale G; Serviddio G
Free Radic Biol Med; 2017 Oct; 111():173-185. PubMed ID: 28109892
[TBL] [Abstract][Full Text] [Related]
17. Lipidomics in non-alcoholic fatty liver disease.
Kartsoli S; Kostara CE; Tsimihodimos V; Bairaktari ET; Christodoulou DK
World J Hepatol; 2020 Aug; 12(8):436-450. PubMed ID: 32952872
[TBL] [Abstract][Full Text] [Related]
18. Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease.
Farrell GC; Haczeyni F; Chitturi S
Adv Exp Med Biol; 2018; 1061():19-44. PubMed ID: 29956204
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis of Nonalcoholic Steatohepatitis.
Machado MV; Diehl AM
Gastroenterology; 2016 Jun; 150(8):1769-77. PubMed ID: 26928243
[TBL] [Abstract][Full Text] [Related]
20. Cellular glutathione in fatty liver in vitro models.
Garcia MC; Amankwa-Sakyi M; Flynn TJ
Toxicol In Vitro; 2011 Oct; 25(7):1501-6. PubMed ID: 21620948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
